94 related articles for article (PubMed ID: 20829635)
21. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
[TBL] [Abstract][Full Text] [Related]
22. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
23. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
24. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Chen CY; Lin TY; Wang CC; Shuai HA
Psychiatry Clin Neurosci; 2011 Feb; 65(1):95-7. PubMed ID: 21265942
[TBL] [Abstract][Full Text] [Related]
25. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
Riedel M; Spellmann I; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Severus E; Engel RR; Müller N; Möller HJ
Pharmacopsychiatry; 2010 Mar; 43(2):50-7. PubMed ID: 20336597
[TBL] [Abstract][Full Text] [Related]
26. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study.
Messer T; Schmauss M; Spevakne-Goeroecs T; Kungel M; Ebrecht M; Werner C; Modell S
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):231-8. PubMed ID: 20218786
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
[TBL] [Abstract][Full Text] [Related]
29. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
30. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
31. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.
Chen SF; Shen YC; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):470-4. PubMed ID: 19302829
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
33. Aripiprazole: pharmacology, efficacy, safety and tolerability.
Kinghorn WA; McEvoy JP
Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
[TBL] [Abstract][Full Text] [Related]
34. Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
Hung GC; Chen YY
Pharmacopsychiatry; 2007 Mar; 40(2):83-4. PubMed ID: 17447180
[No Abstract] [Full Text] [Related]
35. Aripiprazole in the treatment of delirium.
Straker DA; Shapiro PA; Muskin PR
Psychosomatics; 2006; 47(5):385-91. PubMed ID: 16959926
[TBL] [Abstract][Full Text] [Related]
36. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M
World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247
[TBL] [Abstract][Full Text] [Related]
37. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
38. The dysbindin gene (DTNBP1) and schizophrenia: no support for an association in the Korean population.
Joo EJ; Lee KY; Jeong SH; Ahn YM; Koo YJ; Kim YS
Neurosci Lett; 2006 Oct; 407(2):101-6. PubMed ID: 16959423
[TBL] [Abstract][Full Text] [Related]
39. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level.
Stefanis NC; Trikalinos TA; Avramopoulos D; Smyrnis N; Evdokimidis I; Ntzani EE; Ioannidis JP; Stefanis CN
Biol Psychiatry; 2007 Oct; 62(7):784-92. PubMed ID: 17336946
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
